LOPID PATENT EXTENSION SEPARATE BILL SET FOR HOUSE CONSIDERATION: MARKUP JAN. 27
Executive Summary
Rep. Kastenmeier's (D-Wisc.) House Judiciary/Courts Subcommittee, has tentatively scheduled a markup of a separate Lopid patent extension bill for Jan. 27. The scheduling of the markup, only two days after the House returns from the congressional recess, could give the Lopid measure a quick boost in this year's limited Congressional session. The election-year effectively will shorten the legislative calendar. Rep. Derrick's (D-S.C.) HR 3074 would extend the patent for W-L's gemfibrozil, the lipid-lowering agent, by five years through 1994. The patent is currently scheduled to expire July 4, 1989. No amendments to the bill are expected at the markup. The firm was "pleased" with the outcome of an Oct. 8 subcommittee hearing on the bill, at which W-L Chairman Joseph Williams said the firm is willing to commit to five years of price stability for Lopid if the patent extension is granted ("The Pink Sheet" Oct. 12, p. 6). The Lopid extension is based on the premise that Warner-Lambert lost 5-7 years of exclusive marketing under a broader indication in order to conduct a large-scale study in Finland on the effect of Lopid on mortality rates (the Helsinki Heart Study). Lopid was approved in 1981 for a restricted triglyceride-lowering indication. Identical legislation for Lopid has already passed the Senate as an amendment to the omnibus trade bill (HR 3) and is pending before a House/Senate conference committee. As an alternative to passage by the House as an individual bill, Lopid legislation could also pass the House through the conference process. However, the legislation's progress as an individual bill may be quicker: the conference committee has not yet scheduled consideration of the Lopid provision.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth